Sinovac Biotech Ltd.

What they do

The company operates through Chinese mainland subsidiaries including Sinovac Biotech Co., Ltd., Sinovac (Dalian) Vaccine Technology Co., Ltd., Sinovac Life Sciences Co., Ltd., and Sinovac Biomed Co., Ltd., which it lists as its operating entities. Its shares trade on the NASDAQ Global Select Market under the symbol SVA, and it files as a foreign private issuer on Form 20-F. As of December 31, 2025, it reported 71,860,702 common shares outstanding.

Revenue drivers

• Vaccine sales (unallocated in provided excerpts) — The filing excerpts provided do not break out product-level, segment, or customer revenue; reported XBRL revenue was $386.0 million for 2025 against $361.4 million in 2024.
• Chinese mainland operating subsidiaries — Revenue is generated through named Chinese mainland operating subsidiaries such as Sinovac Beijing, Sinovac Dalian, Sinovac LS, and Sinovac Biomed, but the excerpts contain no product-level or segment-level revenue split.

Recent performance

Revenue was $386.0 million in 2025, up from $361.4 million in 2024, after collapsing from $19.37 billion in 2021 and $1.47 billion in 2022 to $470.2 million in 2023. Net income swung to a loss of $198.8 million in 2025 from net income of $40.7 million in 2024, with diluted EPS of negative $0.83 versus $1.27. Operating cash flow was negative $512.2 million in 2025, compared with negative $56.9 million in 2024. At December 31, 2025, total assets were $8.54 billion, total liabilities $2.15 billion, shareholder equity $4.44 billion, cash and equivalents $488.2 million, and long-term debt $494.9 million. Dividends per share of $55 were reported for 2025.

Strategy

The provided excerpts do not describe a specific strategy, pipeline, investment program, or capital allocation plan beyond the reported results. No management guidance or forward-looking targets are quoted in the source material supplied. The only directional data points available are the 2025 dividend per share of $55 and the balance sheet composition at year-end 2025.

Risks

• Severe revenue decline and return to losses — Revenue has fallen from $19.37 billion in 2021 to $386.0 million in 2025, and net income turned negative at $198.8 million in 2025.
• Negative operating cash flow — Operating cash flow was negative $512.2 million in 2025, following negative $56.9 million in 2024.
• Limited liquidity relative to balance sheet — Cash and equivalents were $488.2 million against total liabilities of $2.15 billion and long-term debt of $494.9 million at December 31, 2025.
• Concentration in Chinese mainland operating subsidiaries — The company's named operating entities are all in the Chinese mainland, exposing results to that market, though the supplied excerpts do not quantify the concentration.

Outlook

The provided excerpts do not include management's forward-looking statements, guidance, or outlook commentary. Reported figures are limited to historical results for fiscal years 2021 through 2025 and the December 31, 2025 balance sheet.